AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Net Debt · Q3 FY2025 · quarter ended Sep 2025
Net debt of -€128.26M in Q3 FY2025
Q3 FY2025 net debt was -€128.26M.
Context
- Net debt amounted to 77.4% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
Currency unavailable · from the balance sheet
No Net Debt data reported for this period type.
Net Debt vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Net debt amounts to 77.4% of total assets for AGMB, versus a peer median of 11.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.89M USD | +134.8% | — | 8.8% | |
| Mar 2026 | -$26.68M USD | +4.3% | — | 13.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | -$27.28M USD | +75.9% | — | 4.9% |
| Mar 2026 | -$60.63M USD | -326.8% | — | 96.1% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | -€128.26M EUR | — | — | 77.4% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | +40.1% | — | 11.1% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.